Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Adoption of 2017 Equity Compensation Plan

On November 1, 2017, the Board of Directors (“Board”) of Inspyr Therapeutics, Inc. (“Company”)approved the 2017 Equity Compensation Plan (“Plan). The Plan permits the granting of up to 2,000,000 shares of the Company’s common stock (“Common Stock”) through the issuance of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Stock Appreciation Rights, Restricted Stock Units, Performance Units, Performance Shares, and Other Stock Based Awards to our employees, directors, officers, and consultants.

The foregoing summary of the Plan is qualified in its entirety by reference to the full text of the Plan which is attached hereto as Exhibit 4.01 and which is incorporated herein, in its entirety, by reference.

Item 9.01 Financial Statement and Exhibits.

Exhibit

No.

Description

4.01 2017 Equity Compensation Plan adopted November 1, 2017


Inspyr Therapeutics, Inc. Exhibit
EX-4.01 2 s108007_ex4-01.htm EXHIBIT 4.1 Exhibit 4.01   INSPYR THERAPEUTICS,…
To view the full exhibit click here

About Inspyr Therapeutics, Inc. (OTCMKTS:NSPX)

Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, renal and other cancers. Its technology platform combines a plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that targets the release of the drug within the solid tumor. Its cancer prodrugs provide a targeted therapeutic approach to a range of solid tumors. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Its lead drug candidate, mipsagargin, is activated by the enzyme prostate specific membrane antigen (PSMA), which is found in prostate epithelial cells in the normal prostate, in prostate cancer cells, and in vascular endothelial cells (blood vessels) found in solid tumors. Mipsagargin is in Phase II clinical evaluation in glioblastoma patients.

An ad to help with our costs